Edwards Lifesciences (EW)
(Real Time Quote from BATS)
$69.81 USD
+1.55 (2.27%)
Updated Aug 20, 2024 12:30 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Edwards Lifesciences (EW) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$79.13 | $91.00 | $65.00 | 15.92% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Edwards Lifesciences comes to $79.13. The forecasts range from a low of $65.00 to a high of $91.00. The average price target represents an increase of 15.92% from the last closing price of $68.26.
Analyst Price Targets (24)
Broker Rating
Edwards Lifesciences currently has an average brokerage recommendation (ABR) of 2.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 2.32 a month ago based on 25 recommendations.
Of the 26 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 38.46% and 3.85% of all recommendations. A month ago, Strong Buy made up 40%, while Buy represented 4%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/EW.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 14 | 15 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 14 | 14 | 12 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 2 | 2 | 2 |
ABR | 2.27 | 2.27 | 2.32 | 2.00 | 1.96 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/31/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
7/30/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
7/29/2024 | Not Identified | Not Identified | Strong Sell | Hold |
7/25/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Hold |
7/25/2024 | Truist Securities | Richard Newitter | Hold | Hold |
7/25/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
7/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/25/2024 | UBS | Danielle Antalffy | Hold | Hold |
7/25/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Hold |
7/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/25/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
7/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | SVB Securities | Michael Kratky | Hold | Hold |
6/21/2024 | BTIG | Marie Thibault | Hold | Hold |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Strong Buy |
5/22/2024 | Not Identified | Not Identified | Hold | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
4/26/2024 | Piper Sandler | Adam C Maeder | Hold | Hold |
4/8/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.27 |
ABR (Last week) | 2.27 |
# of Recs in ABR | 26 |
Average Target Price | $79.13 |
LT Growth Rate | 8.90% |
Industry | Medical - Instruments |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | 0.68 |